To enhance the therapeutic outcome for advanced prostate carcinoma, the authors studied retrospectively 22 cases of advanced prostate carcinoma, which were treated by orchiectomy with oral Flutamide. Among 22 cases, state C 2 was 8, D 1 was 9,and D 2 was 5 respectively.
Treatment of advanced prostatic cancer with anti-androgens alone and a combination of anti-androgen with anti-prolactine - A pil
In this pilot study the treatment of advanced prostatic cancer with cyproteronacetate (AndrocurR) is compared with the treatment of a lower dose cyproteronacetate plus lisuride (DoperginR), an anti-prolactin derivative.
According to these findings it is suggested that PSA is more sensitive than PAP in local and advanced prostatic cancer and may be more useful in monitoring responses and recurrence after therapy.
Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer
A new slow-release formulation of buserelin given as a 3-month depot injection was evaluated in four patients with advanced prostatic cancer.
Effect of intermittent androgen blockade on the quality of life of patients with advanced prostate carcinoma
Gammopathy associated with advanced prostate carcinoma
Patients and methods: Patients eligible for this study had advanced prostate carcinoma that had failed hormonal treatment.
Although the percentage of neuroendocrine differentiation was greater in advanced prostate carcinoma (stage C, D) than localized (stage A, B) the difference was not statistically significant (p = 0.18).